SecBot SecBot
6-K ·Filed Jun 29, 2026

GMAB

GENMAB A/S
BULLISH
Impact 7/10
Horizonweeks Processed4mo ago SEC0001434265-26-000100
Notable filing: 6-K
Actionable Insight ▲ Bullish

This positive Phase 3 data is a strong catalyst for Genmab, supporting epcoritamab's label expansion into a large DLBCL market. Traders should monitor regulatory submissions and upcoming medical meeting presentations for full data. The strong hazard ratios suggest a high likelihood of approval, which could drive upside. Watch for competitor responses from CAR-T and other bispecifics.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$27.47
T+0 close · Jun 29, 2026 · via day close
Latest settled
+26.50%
T+60 · $34.75
Vs SPY
+23.68%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 30 $27.47entry
  2. T+1 · 5mo ago +0.62%α +0.75% · $27.64
  3. T+5 · 4mo ago +1.97%α +1.36% · $28.01
  4. T+20 · 4mo ago +4.84%α +5.87% · $28.80
  5. T+60 · 8w ago +26.50%α +23.68% · $34.75
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Genmab announced positive topline Phase 3 results for epcoritamab plus lenalidomide in relapsed/refractory DLBCL, meeting the primary endpoint with statistically significant improvement in progression-free survival (PFS). The risk of disease progression and death was reduced by 60% (HR 0.40) and 56% (HR 0.44) under different censoring rules, with safety consistent with individual agents. This is a major clinical win that supports label expansion and strengthens epcoritamab's position as a core therapy in B-cell malignancies.

Key Facts

  • Phase 3 EPCORE DLBCL-4 trial met primary endpoint with statistically significant improvement in PFS
  • Risk reduction of 60% (HR 0.40, 95% CI 0.30-0.55, p<0.0001) in the U.S. and 56% (HR 0.44, 95% CI 0.33-0.60, p<0.0001) outside the U.S.
  • Safety profile of epcoritamab plus lenalidomide consistent with known profiles of individual agents
  • Genmab and AbbVie will engage global regulatory authorities for potential label expansion
  • Epcoritamab is already approved in >65 territories for certain lymphoma indications

Financial Impact

Potential label expansion in RR DLBCL could significantly increase epcoritamab revenue; no specific financial guidance provided in the filing.

revenuepipeline value

Risk Factors

  • Regulatory approval is not guaranteed; full data and safety details are pending
  • Competition from CAR-T therapies and other bispecific antibodies in DLBCL
  • Potential for unforeseen safety signals in larger patient populations

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
76% bullish (25 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001434265-26-000100
Document: gmab_20260629x6k.htm0001434265-26-000100
Document: 0001434265-26-000100-index-headers.html0001434265-26-000100
Document: 0001434265-26-000100-index.html0001434265-26-000100
Document: 0001434265-26-000100.txt0001434265-26-000100

US Market Status

Market Closed · Opens in 9h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 29, 2026